Biotechnology

Adaptimmune Therap

Adaptimmune Therapeutics Director Ali Behbahani Sells Shares

Adaptimmune Therap released FY2025 Semi-Annual earnings on August 13 (EST), actual revenue USD 20.96 M, actual EPS USD -0.2999

Adaptimmune Therap released FY2025 Q2 earnings on August 13 (EST), actual revenue USD 13.68 M (forecast USD 8.963 M), actual EPS USD -0.1199 (forecast USD -0.09)

Adaptimmune Therapeutics stock breaks above 50-day moving average

Bank of America Cuts Stake in Adaptimmune

Adaptimmune Therapeutics plc receives analyst ratings and target price adjustments

Adaptimmune Therap released FY2025 Q1 earnings on May 13 Pre-Market EST, actual revenue USD 7.285 M (forecast USD 6.551 M), actual EPS USD -0.1851 (forecast USD -0.1375)

Adaptimmune Therapeutics plc Reports Q1 2025 Financials

Adaptimmune Therapeutics EPS forecasted at -0.17 before Q1 earnings release

Adaptimmune Therap to release FY2025 Q1 earnings on May 13 Pre-Market EST, forecast revenue USD 6.551 M, EPS USD -0.1375

Adaptimmune Therapeutics plc Gains Additional Compliance Period

Adaptimmune Therapeutics released FY2024 Q4 earnings on March 24 Pre-Market (EST), actual revenue 3.222 M USD (forecast 8.181 M USD), actual EPS -0.309 USD (forecast -0.155 USD)

Adaptimmune Therapeutics released FY2024 annual earnings on March 24 Pre-Market (EST), actual revenue $178.03M (forecast $182.99M), actual EPS -$0.3 (forecast -$0.145)

Adaptimmune Therap to Release FY2024 Q4 Earnings on March 20, 2025, Pre-Market EST; Forecasted Revenue: 8.419 M USD, EPS: -0.155 USD

Adaptimmune Therapeutics released FY2024 Q3 earnings on November 13 After-Market (EST), actual revenue 40.9 MUSD (forecast 20.49 MUSD), actual EPS -0.0688 USD (forecast -0.078 USD)

Adaptimmune Therapeutics released FY2024 Cumulative Q3 Earnings on November 13, 2024 (EST) with Revenue of 174.81M USD and EPS of -0.0294

Adaptimmune Therapeutics to Release FY2024 Q3 Earnings on November 13 After-Market EST, Forecast Revenue 20.49 M USD, EPS -0.078 USD

Adaptimmune Advances T-Cell Receptor Therapy

The US Food and Drug Administration (FDA) has approved Tecelra from Adaptimmune Therapeutics

Rich Sparkle

Novabay Pharmac

Valens Semiconductor

Greenpower Motor

Alpha Tech

Offerpad Solutions

VCI Global

Tryhard

Tradr 2X Long APLD Daily ETF

ZeZentalis Pharma

ADMA生物制藥

Kiniksa Pharmaceuticals

Stoke Therapeutics

Rigel制藥

OpGen

福泰制藥

再生元制藥

阿里拉姆制藥

Argenx

百濟神州

Style Score

Growth Score

Revenue YoY

Net Profit YoY

Value Score

P/B Ratio

Dividend Ratio

Size Score

Market Cap Score

Market Cap

Revenue Score

Revenue

Multi Score

Profit Score

Profit Margin

Gross Margin

Total Assets YoY

Net Assets YoY

Cash Score

Cash Flow Margin

OCF YoY

Operating Score

Turnover

Debt Score

Gearing Ratio

Please note that a "Suspected value trap" is a stock that appears The stock looks financially sound and severely undervalued, but behind the low valuation is a long-term decline in business capacity or a serious financial crisis, or even the risk of bankruptcy in the short term.

Suspected value trap

Adaptimmune Therap(ADAP.US)